Drug intelligence / Profile preview

DW-MSC

Development stage: Phase 1
Lead developer: Daewoong Pharmaceutical
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

DW-MSC is a mesenchymal stem cell (MSC) therapy developed by Daewoong Pharmaceutical. It utilizes human-derived mesenchymal stem cells, known for their pluripotent capabilities and significant immunomodulatory properties. The therapy is designed to mitigate hyper-inflammatory responses (such as the cytokine storm) and promote tissue regeneration in the lungs and other organs. Its clinical development has primarily focused on treating respiratory distress associated with viral infections, including COVID-19, SARS, and MERS, where it aims to improve clinical outcomes by regulating immune system activity and repairing damaged alveolar tissues.

Other names: allogeneic mesenchymal stem cells-Ina-Respond-COVID-19allogeneic mesenchymal stem cells

Beyond the preview

Go deeper on DW-MSC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-MSC.

Explore the full profile